233 related articles for article (PubMed ID: 16488082)
1. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
2. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
6. Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Karpel-Massler G; Wirtz CR; Halatsch ME
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):384-94. PubMed ID: 21612575
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
8. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
[TBL] [Abstract][Full Text] [Related]
9. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
10. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
Loew S; Schmidt U; Unterberg A; Halatsch ME
Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
[TBL] [Abstract][Full Text] [Related]
12. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib in glioblastoma: lost in translation?
Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Rosell R; Taron M; Reguart N; Isla D; Moran T
Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
[TBL] [Abstract][Full Text] [Related]
16. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract][Full Text] [Related]
20. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
